AAAAAA

   
Results: 1-25 |
Results: 25

Authors: COMBEAU C KENIGSBERG M BAZIN V LAVELLE F MELKI R
Citation: C. Combeau et al., EXPRESSION OF GAMMA-TUBULIN AND THE CYTOPLASMIC CHAPERONIN CONTAININGTCP-1 (CCT) IN TUMOR-CELL LINES AND DURING CELL-PROLIFERATION - A COMPARATIVE-STUDY, Molecular biology of the cell, 9, 1998, pp. 874-874

Authors: LAVELLE F
Citation: F. Lavelle, PRECLINICAL EVALUATION OF ANTICANCER DRUGS, Bulletin du cancer, 85(10), 1998, pp. 837-842

Authors: LAVELLE F JEHANNO A
Citation: F. Lavelle et A. Jehanno, ANTITUMOR AGENTS - REALITIES AND PERSPECT IVES IN 1998, Bulletin du cancer, 85(1), 1998, pp. 83-88

Authors: BISSERY MC VRIGNAUD P LAVELLE F
Citation: Mc. Bissery et al., IN-VIVO EVALUATION OF THE IRINOTECAN-OXALIPLATIN COMBINATION, European journal of cancer, 33, 1997, pp. 793-793

Authors: LAVELLE F
Citation: F. Lavelle, TYROSINE PROTEIN-KINASE INHIBITORS IN ONC OLOGY - THE END OF THE BEGINNING, Bulletin du cancer, 84(7), 1997, pp. 769-770

Authors: BISSERY MC VRIGNAUD P LAVELLE F CHABOT GG
Citation: Mc. Bissery et al., EXPERIMENTAL ANTITUMOR-ACTIVITY AND PHARMACOKINETICS OF THE CAMPTOTHECIN ANALOG IRINOTECAN (CPT-11) IN MICE, Anti-cancer drugs, 7(4), 1996, pp. 437-460

Authors: ROCHEFORT P CAILLOU B MICHIELS FM LEDENT C TALBOT M SCHLUMBERGER M LAVELLE F MONIER R FEUNTEUN J
Citation: P. Rochefort et al., THYROID PATHOLOGIES IN TRANSGENIC MICE EXPRESSING A HUMAN ACTIVATED RAS GENE DRIVEN BY A THYROGLOBULIN PROMOTER, Oncogene, 12(1), 1996, pp. 111-118

Authors: LAVELLE F BISSERY MC ANDRE S ROQUET F RIOU JF
Citation: F. Lavelle et al., PRECLINICAL EVALUATION OF CPT-11 AND ITS ACTIVE METABOLITE SN-38, Seminars in oncology, 23(1), 1996, pp. 11-20

Authors: GOBERT C BRACCO L ROSSI F OLIVIER M TAZI J LAVELLE F LARSEN AK RIOU JF
Citation: C. Gobert et al., MODULATION OF DNA TOPOISOMERASE-I ACTIVITY BY P53, Biochemistry, 35(18), 1996, pp. 5778-5786

Authors: BOURZAT JD LAVELLE F COMMERCON A
Citation: Jd. Bourzat et al., SYNTHESIS AND BIOLOGICAL-ACTIVITY OF PARASUBSTITUTED 3'-PHENYL DOCETAXEL ANALOGS, Bioorganic & medicinal chemistry letters, 5(8), 1995, pp. 809-814

Authors: BISSERY MC NOHYNEK G SANDERINK GJ LAVELLE F
Citation: Mc. Bissery et al., DOCETAXEL (TAXOTERE(R)) - A REVIEW OF PRECLINICAL AND CLINICAL-EXPERIENCE .1. PRECLINICAL EXPERIENCE, Anti-cancer drugs, 6(3), 1995, pp. 339-355

Authors: NGUYEN CH FAN E RIOU JF BISSERY MC VRIGNAUD P LAVELLE F BISAGNI E
Citation: Ch. Nguyen et al., SYNTHESIS AND BIOLOGICAL EVALUATION OF AMINO-SUBSTITUTED BENZO[F]PYRIDO[4,3-B] AND PYRIDO[3,4-B]QUINOXALINES - A NEW CLASS OF ANTINEOPLASTIC AGENTS, Anti-cancer drug design, 10(4), 1995, pp. 277-297

Authors: MAILLIET P SEGALBENDIRDJIAN E KOZELKA J BARREAU M BAUDOIN B BISSERY MC GONTIER S LAOUI A LAVELLE F LEPECQ JB CHOTTARD JC
Citation: P. Mailliet et al., ASYMMETRICALLY SUBSTITUTED ETHYLENEDIAMINE PLATINUM(II) COMPLEXES AS ANTITUMOR AGENTS - SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS, Anti-cancer drug design, 10(1), 1995, pp. 51-73

Authors: BISSERY MC VRIGNAUD P LAVELLE F
Citation: Mc. Bissery et al., PRECLINICAL PROFILE OF DOCETAXEL (TAXOTERE) - EFFICACY AS A SINGLE-AGENT AND IN COMBINATION, Seminars in oncology, 22(6), 1995, pp. 3-16

Authors: LAVELLE F BISSERY MC COMBEAU C RIOU JF VRIGNAUD P ANDRE S
Citation: F. Lavelle et al., PRECLINICAL EVALUATION OF DOCETAXEL (TAXOTERE), Seminars in oncology, 22(2), 1995, pp. 3-16

Authors: LAVELLE F COMBEAU C COMMERCON A
Citation: F. Lavelle et al., TAXOIDS - STRUCTURAL AND EXPERIMENTAL PRO PERTIES, Bulletin du cancer, 82(4), 1995, pp. 249-264

Authors: OJIMA I DUCLOS O KUDUK SD SUN CM SLATER JC LAVELLE F VEITH JM BERNACKI RJ
Citation: I. Ojima et al., SYNTHESIS AND BIOLOGICAL-ACTIVITY OF 3'-ALKYL-3'-DEPHENYLDOCETAXEL AND 3'-ALKENYL-3'-DEPHENYLDOCETAXEL, Bioorganic & medicinal chemistry letters, 4(21), 1994, pp. 2631-2634

Authors: OJIMA I DUCLOS O ZUCCO M BISSERY MC COMBEAU C VRIGNAUD P RIOU JF LAVELLE F
Citation: I. Ojima et al., SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF NEW ANTITUMOR TAXOIDS - EFFECTS OF CYCLOHEXYL SUBSTITUTION AT THE C-3' AND OR C-2 OF TAXOTERE (DOCETAXEL)/, Journal of medicinal chemistry, 37(16), 1994, pp. 2602-2608

Authors: NABIEV I CHOURPA I RIOU JF NGUYEN CH LAVELLE F MANFAIT M
Citation: I. Nabiev et al., MOLECULAR-INTERACTIONS OF DNA TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITOR WITH DNA AND TOPOISOMERASES AND IN TERNARY COMPLEXES - BINDINGMODES AND BIOLOGICAL EFFECTS FOR INTOPLICINE DERIVATIVES, Biochemistry, 33(30), 1994, pp. 9013-9023

Authors: BISSERY MC NGUYEN CH BISAGNI E VRIGNAUD P LAVELLE F
Citation: Mc. Bissery et al., ANTITUMOR-ACTIVITY OF INTOPLICINE (RP-60475, NSC-645008), A NEW BENZOPYRIDO-INDOLE - EVALUATION AGAINST SOLID TUMORS AND LEUKEMIAS IN MICE, Investigational new drugs, 11(4), 1993, pp. 263-277

Authors: PODDEVIN B RIOU JF LAVELLE F POMMIER Y
Citation: B. Poddevin et al., DUAL TOPOISOMERASE-I AND TOPOISOMERASE-II INHIBITION BY INTOPLICINE (RP-60475), A NEW ANTITUMOR AGENT IN EARLY CLINICAL-TRIALS, Molecular pharmacology, 44(4), 1993, pp. 767-774

Authors: RIOU JF FOSSE P NGUYEN CH LARSEN AK BISSERY MC GRONDARD L SAUCIER JM BISAGNI E LAVELLE F
Citation: Jf. Riou et al., INTOPLICINE (RP-60475) AND ITS DERIVATIVES, A NEW CLASS OF ANTITUMOR AGENTS INHIBITING BOTH TOPOISOMERASE-I AND TOPOISOMERASE-II ACTIVITIES, Cancer research, 53(24), 1993, pp. 5987-5993

Authors: MORJANI H RIOU JF NABIEV I LAVELLE F MANFAIT M
Citation: H. Morjani et al., MOLECULAR AND CELLULAR INTERACTIONS BETWEEN INTOPLICINE, DNA, AND TOPOISOMERASE-II STUDIED BY SURFACE-ENHANCED RAMAN-SCATTERING SPECTROSCOPY, Cancer research, 53(20), 1993, pp. 4784-4790

Authors: LAVELLE F GUERITTEVOEGELEIN F GUENARD D
Citation: F. Lavelle et al., TAXOTERE - FROM YEWS NEEDLES TO PATIENTS, Bulletin du cancer, 80(4), 1993, pp. 326-338

Authors: RIOU JF GRONDARD L PETITGENET O ABITBOL M LAVELLE F
Citation: Jf. Riou et al., ALTERED TOPOISOMERASE-I ACTIVITY AND RECOMBINATION ACTIVATING GENE-EXPRESSION IN A HUMAN LEUKEMIA-CELL LINE RESISTANT TO DOXORUBICIN, Biochemical pharmacology, 46(5), 1993, pp. 851-861
Risultati: 1-25 |